Focus on innovation! Roche led the creation of the Lung Cancer Rare Target Ecological Alliance

On November 5, the 5th China International Import Expo (hereinafter referred to as the "Expo") opened, in this grand event, Roche continued to deepen its efforts in the field of lung cancer: Roche Pharmaceutical, Roche Diagnostics and partners signed a contract to establish a lung cancer rare target ecological alliance at the Expo , jointly with CSCO and Professor Zhou Caicun to update and release the second edition of the "ALK-positive NSCLC Patients Survival Status Survey White Paper"
.
At the same time, the "Jinbo baby" entlitinib (Luo Shengquan) also launched the listing ceremony at the Expo, which is Roche's after aletitinib (An Shengsha ® ®), New commitments
in the field of rare target therapy for lung cancer.

Together, the Lung Cancer Rare Target Ecological Alliance was established

On November 6, Roche Pharmaceutical signed a contract with seven companies, including Genetron, BGI, Jinyu Medical, Jiyinga, Ranshi Medical, Zhiben Medical and Zhenhe Biotechnology, to establish a lung cancer rare target ecological alliance, and all parties will strengthen cooperation in the fields of improving the standardized diagnosis and treatment of rare lung cancer targets and patient education.
It aims to explore innovative medical solutions and jointly contribute to the construction of local medical innovation ecosystem to benefit Chinese patients
.

Signing ceremony of the Lung Cancer Rare Target Ecological Alliance

In the cooperation of first-tier cities, the Lung Cancer Rare Target Alliance will be committed to promoting the construction of a standardized diagnosis and treatment demonstration center for rare lung cancer in China, building a platform for academic exchanges and inter-hospital cooperation between the centers, jointly playing a leading role in demonstration, continuing to deepen the management of the quality of diagnosis and treatment of rare targets for lung cancer, and working together to help improve the level of lung cancer prevention and treatment in
China.

Ms.
Liu Yan, Chief Commercial Officer of Genetron, said, "As a pioneer in the field of precision medicine for cancer in China, Genetron has always taken technological innovation as the source of enterprise development, and has continuously applied advanced molecular detection technology and cutting-edge discovery in cancer full-cycle management
.
This cooperation with Roche looks forward to joining forces to help improve the level of lung cancer prevention and treatment and contribute to 'Healthy China'
.
"

Mr.
Han Yusheng, Founder and CEO of Ranshi Medicine, said, "The establishment of the Rare Target Ecological Alliance for Lung Cancer will integrate the resources and advantages of both Roche and Ranshi Medical to jointly improve the concept of precise diagnosis and treatment of
thoracic surgery and lung cancer patients.
Through the in-depth cooperation of 'diagnosis' and 'treatment', we will build an integrated solution for the diagnosis and treatment of rare targets, promote the better application of new technologies and achievements in the clinic, and promote the standardized development of the field of precision medicine for lung cancer ”
。

Dr.
Wang Haibo, Vice President of Zhenhe Technology, emphasized: "Taking the signing as the starting point, we will concentrate the advantages of all parties, share cutting-edge ideas, promote the application of new technologies, help the precise diagnosis and treatment of lung cancer, and bring more survival and benefit opportunities
for patients.
" Zhenhe Technology will give full play to its advantages in precision cancer detection, fully support the work of the Alliance, and contribute to the realization of the goal of Healthy China.
"

Dr.
Leilei Lu, Chief Operating Officer of Zhiben Medical, said: "As a leader in precision diagnosis and treatment companies in China, Zhiben Medical has always been committed to using next-generation sequencing technology to promote the implementation of innovative diagnosis and innovative payment in China, and providing innovative solutions and whole-process management services for Chinese patients with the help of cooperation platforms"
.

In the vast area, the Lung Cancer Rare Target Ecological Alliance will be committed to popularizing advanced detection technology and diagnosis and treatment concepts, comprehensively improving the standardized diagnosis and treatment ability of grassroots doctors for rare lung cancer through offline lectures and distance education, helping to strengthen and optimize the construction of the grassroots standardized diagnosis and treatment grid, and helping lung cancer patients get standardized, reasonable and timely diagnosis and treatment
at their doorstep.

To this end, Zhu Shida, deputy general manager of BGI, said that it is of great significance
to see the establishment of the Rare Target Ecological Alliance for lung cancer, the large patient base of lung cancer, the improvement of rare target detection capabilities, and the establishment of accurate and standardized clinical diagnosis and treatment standards, which can benefit more patients.
BGI will rely on the closed-loop tumor gene testing product service matrix of "pre-screening diagnosis and supervision" to provide accurate and inclusive testing services and help improve the level
of precision cancer medicine in China.

Mr.
Liu Shengwei, Vice President of Jinyu Medical and General Manager of the Group's Marketing Operation Center, also believed: "With the development of precision medicine, genetic testing has been given great significance to guide tumor patients to use drugs, but the overall detection level of rare genes in the industry is still insufficient
.
Golden Mile Medical has a comprehensive and diverse genetic testing platform and a nationwide service network, and looks forward to jointly helping to improve the level of precision diagnosis and treatment of tumors in China through the establishment of the alliance.
"

Mr.
Shengke, Director of Pharmaceutical Enterprise Services of Beijing Jiinga Technology Co.
, Ltd.
: "Jiinga will be committed to promoting the construction of a standardized diagnosis and treatment demonstration center for rare targets of lung cancer, continuing to deepen the construction of a grid for the diagnosis and treatment of rare targets of lung cancer, and working with partners to help prevent and treat lung cancer, so as to achieve a standardized, reasonable and timely diagnosis and treatment new ecology
.
" It is hoped that through the establishment of regional testing centers, extensive cooperation will be carried out to help standardize the diagnosis and treatment
of rare targets of lung cancer.
”

In addition, the Lung Cancer Rare Target Ecological Alliance will also be committed to patient education, focusing on the accurate diagnosis, standardized treatment, and disease management of rare targets of lung cancer, so as to avoid the situation of
danger without screening, screening without investigation, and investigation without treatment.
In addition, it will provide all-round care support
in innovative payment, convenient drug purchase, and patient communication.

Roche Pharma has always adhered to the concept of "acting first for the needs of patients", and has always been at the forefront of innovative drug research, in ALK, ROS1, NTRK and other rare target fields have laid out a variety of innovative products
.
The domestic approval of entretinib has lit up a new hope
for rare target patients.

Emtratinib is on the market, and there is a rare new dawn of the target

The incidence of ROS1 in non-small cell lung cancer is approximately 2 percent[1].

In 2022, entitrutinib was officially approved as an indication for ROS1-positive adult patients with locally advanced or metastatic NSCLC and NTRK fusion-positive solid tumors
.

Luo Shengquan's ® listing launch ceremony

Data updated at the 2022 World Congress of Lung Cancer (WCLC) show that entretinib has an overall objective response rate (ORR) in first-line treatment for patients with ROS1-positive NSCLC ) reached 68.
7%, the median duration of response (DOR) was nearly three years (35.
6 months), and the median progression-free survival (PFS) was reached 17.
7 months, median overall survival (OS) nearly four years (47.
7 months) [2].

It is believed that with the successive launch of innovative therapies represented by entretinib, Chinese patients will have better clinical choices
.
With the increase of patients' treatment choices, how to achieve accurate diagnosis, standardized treatment, achieve better quality of survival, and realize the chronic disease of lung cancer has become a new clinical challenge
.

Lung cancer is a rare target, and the white paper for ALK-positive patients has been upgraded

On November 6, Professor Zhou Caicun, Chairman of CSCO Non-Small Cell Lung Cancer Committee and Shanghai Pulmonary Hospital affiliated to Tongji University, released a new version of "2022 ALK Positive NSCLC" at the Expo White Paper on the Status of Patient Survival.

Professor Zhou Caicun released the "2022 White Paper on the Survival Status of ALK-positive Patients with Non-Small Cell Lung Cancer"

ALK is common in lung cancer groups that are younger and have no smoking history, accounting for about 3%~7% of
NSCLC patients.
Compared with last year, this year's white paper covers a wider research area, and the patient sample size has expanded to more than 3,000, which is currently the world's largest ALK+ NSCLC patient survey
.
At the same time, a broader and deeper multi-dimensional analysis was carried out to better present the current status, quality and difficulties of treatment, life and survival of ALK-positive NSCLC patients, and to gain insight into unmet clinical needs and the direction
of patient service improvement.
 

In his speech, Professor Zhou shared that more than half of ALK+NSCLC patients are locally late/advanced at the time of diagnosis, and the proportion of baseline brain metastases in stage IV patients reaches 27%.

In first-line treatment, 80% of patients will choose targeted drugs, of which aletitinib accounts for about 67%, and it has excellent
patient satisfaction with treatment.
However, constipation, rash, and liver injury in first-line treatment are the adverse reactions that have the greatest impact on the quality of life of patients, and the disease progresses rapidly, usually within 1-3 years, with brain metastases as the main part
.

In second-line therapy, targeted therapy is still the main choice for patients, but overall satisfaction needs to be improved
.
At the same time, the high price of treatment is still one of the clinical pain points, and the average treatment cost of ALK+NSCLC exceeds 200,000 yuan, and improving the accessibility of innovative drugs will also be one of the challenges of
clinical treatment.

epilogue

Listing of entrelatinib in China, 2022 The release of the white paper on the survival status of ALK-positive non-small cell lung cancer patients and the establishment of the Lung Cancer Rare Target Ecological Alliance not only demonstrate Roche's patient-centered corporate responsibility, but also fulfill the "Healthy China 2030" planning outline It puts forward the social responsibility of "jointly building and sharing the health of the whole people", optimizing health services, and better meeting the health needs of the masses.

References

[1] Cancers (Basel).
2020 Nov; 12(11): 3293.

[2] MA13.
04-Entrectinib in Patients with ROS1 Fusion-Positive NSCLC: Updated Efficacy and Safety Analysis.
WCLC 2022